OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Naumann on Neoadjuvant Chemotherapy in Patients With Ovarian Cancer

August 24th 2018

R. Wendel Naumann, MD, gynecologic oncologist, Levine Cancer Institute, Carolinas HealthCare System, discusses the use of neoadjuvant chemotherapy in patients with ovarian cancer.

Dr. Levy on Biomarkers of Response to Immunotherapy

August 24th 2018

Benjamin P. Levy, MD, assistant professor of oncology, clinical director of medical oncology, Johns Hopkins Sidney Kimmel Cancer Center, Johns Hopkins Medicine, discusses biomarkers of response to immunotherapy.

Dr. Hobbs Discusses the Treatment Landscape of CML

August 24th 2018

Gabriela S. Hobbs, MD, clinical director, Leukemia Service, assistant in medicine, Massachusetts General Hospital, discusses the treatment landscape of chronic myeloid leukemia.

Dr. Bekaii-Saab Discusses Regorafenib Use in mCRC

August 24th 2018

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses regorafenib (Stivarga) use in metastatic colorectal cancer (mCRC).

Dr. Scagliotti on Immunotherapy and Precision Medicine in Lung Cancer

August 24th 2018

Giorgio Vittorio Scagliotti, MD, PhD, chief of the Medical Oncology Division at the S. Luigi Hospital, Orbassano (Torino), and head of the Department of Oncology at University of Torino, Italy, discusses immunotherapy in the context of precision medicine in lung cancer.

Dr. Powell on MSI and dMMR as Potential Biomarkers in Endometrial Cancer

August 24th 2018

Matthew Powell, MD, associate professor, Obstetrics and Gynecology, Division of Gynecologic Oncology, Washington University School of Medicine, discusses microsatellite instability and mismatch repair deficiency as potential biomarkers in endometrial cancer.

Dr. Formenti on the Role of the Immune System in Cancer Treatment

August 24th 2018

Silvia Chiara Formenti, MD, chair, Department of Radiation Oncology, Weill Cornell, associate director, Meyer Cancer Center, radiation oncologist-in-chief, NewYork-Presbyterian Hospital, discusses the role of the immune system in cancer treatment.

Dr. Youngblood on the Process of T-Cell Differentiation in Pediatric Solid Tumors

August 23rd 2018

Benjamin A. Youngblood, PhD, assistant member, Department of Immunology, St. Jude Children’s Research Hospital, discusses the process of T-cell differentiation in pediatric solid tumors.

Dr. Singal Discusses Sequencing Therapy for HCC

August 23rd 2018

Amit G. Singal, MD, associate professor, UT Southwestern Medical Center, discusses sequencing therapy for patients with hepatocellular carcinoma.

Dr. Jabbour Discusses Recent Advancements in ALL

August 23rd 2018

Elias Jabbour, MD, an associate professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, discusses recent advances in the treatment of patients with acute lymphoblastic leukemia.

Dr. Denes Discusses Biosimilar Pricing in Oncology

August 23rd 2018

Alex E. Denes, MD, associate professor of medicine, School of Medicine, Oregon Health and Science University, discusses biosimilar pricing in oncology.

Dr. Camidge on the KEYNOTE-024 Trial in NSCLC

August 23rd 2018

D. Ross Camidge, MD, PhD, professor, Division of Medical Oncology, Joyce Zeff Chair in Lung Cancer Research, School of Medicine, Division of Medical Oncology, University of Colorado, discusses implications of the KEYNOTE-024 trial in non–small cell lung cancer (NSCLC).

Dr. Coleman on Immunotherapy in Ovarian Cancer

August 23rd 2018

Robert Coleman, MD, professor in the department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, discusses ongoing research with immunotherapy in ovarian cancer.

Dr. Tripathy on Frontline Endocrine Therapies in HR+ Breast Cancer

August 23rd 2018

Debu Tripathy, MD, professor and chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses frontline endocrine therapies for patients with hormone receptor (HR)-positive breast cancer.

Dr. Borgen on Deciding Factors of Lymph Node Dissection in Breast Cancer

August 23rd 2018

Patrick Borgen, MD, chair, Department of Surgery, director, Breast Center, Maimonides Medical Center, discusses important factors of deciding which patients with breast cancer need axillary lymph node dissection.

Dr. Brown on the Adoption of Genetic Testing

August 22nd 2018

Jubilee Brown, MD, professor of gynecologic oncology, Levine Cancer Institute, Carolinas HealthCare System, discusses the adoption of genetic testing into routine clinical practice.

Dr. Hall on Combination Approaches in Advanced NSCLC

August 22nd 2018

Richard D. Hall, MD, assistant professor, Hematology/Oncology, University of Virginia Health System, discusses combination approaches in advanced non–small cell lung cancer (NSCLC).

Dr. Ellis Considers the Use of Biosimilars in Oncology

August 22nd 2018

Matthew J. Ellis, MD, PhD, professor and director, Lester and Sue Smith Breast Center, associate director of Precision Medicine, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, discusses considerations for the use of biosimilars in oncology.

Dr. Madduri on Eligibility for CAR T-Cell Therapy in Myeloma

August 22nd 2018

Deepu Madduri, MD, assistant professor, Mount Sinai Hospital, discusses eligibly criteria for patients with multiple myeloma to receive chimeric antigen receptor (CAR) T-cell therapy.

Dr. O'Brien Discusses Combination Venetoclax in CLL

August 22nd 2018

Susan M. O’Brien, MD, hematologist/oncologist at University of California, Irvine Health, discusses combination venetoclax (Venclexta) in the treatment of patients with chronic lymphocytic leukemia.